Use second-generation antihistamines first

Second-generation antihistamines provide better chronic urticaria control with less sedation than first-generation agents.
*Systematic review and network meta-analysis of randomized trials; Level 1a.

Citation

Chu AWL, Zhao IX, Rayner DG, et al. Comparative efficacy and safety of antihistamines, increased antihistamine dosing, and antihistamine adjuncts for chronic urticaria. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.09.030

Background

Chronic urticaria causes recurrent hives, itching, swelling, and sleep disruption for more than 6 weeks. Antihistamines are first-line treatment, but optimal drug choice and dose escalation remain uncertain.

Patients

22,187 children and adults with chronic urticaria in 211 randomized trials. Acute urticaria, nonrandomized studies, and trials with major data-integrity concerns were excluded.

Intervention

Oral antihistamines, higher antihistamine doses, or add-on montelukast or an H2 blocker.

Control

Placebo, another antihistamine, or standard-dose second-generation antihistamine alone.

Outcome

Urticaria activity using UAS7 (0 to 42), itch/wheal/sleep scores (0 to 3), quality of life using DLQI (0 to 30), swelling, sedation, and adverse events.

Follow-up Period

Median 4 weeks; range about 4 days to 12 weeks.

Results

Finding Effect
Second-generation vs first-generation: urticaria activity MD -2.51 (95% CrI -5.01 to -0.02); NNT ≈10
Add montelukast to second-generation antihistamine: urticaria activity MD -3.28 (95% CrI -5.87 to -0.68); NNT ≈9
Add montelukast: quality of life MD -3.32 (95% CrI -5.69 to -0.95); NNT ≈6
Doxepin or many first-generation agents: sedation OR 9.16 (95% CrI 3.96 to 21.21); NNH ≈5
Cetirizine: sedation OR 2.71 (95% CrI 1.80 to 4.07); NNH ≈20

UAS7: 7-day Urticaria Activity Score. DLQI: Dermatology Life Quality Index. MD: mean difference. OR: odds ratio. CrI: credible interval. NNT: number needed to treat. NNH: number needed to harm.

Bilastine, desloratadine, and fexofenadine combined strong symptom benefit with low sedation. Higher doses may add benefit, but gains diminished and sedation increased.

Limitations

Trials were mostly short, varied in outcome measurement, and rarely reported swelling outcomes. Long-term harms and hyperactivity or confusion were not well studied.

Funding

AAAAI/ACAAI guideline funding; scope input only.

Clinical Application

Prefer second-generation antihistamines; avoid first-generation agents when possible. Consider limited dose escalation or montelukast add-on through shared decision-making.